Dynamic Lymphocyte Changes Following Transarterial Radioembolization: Association with Normal Liver Dose and Effect on Overall Survival

References

• Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155–1163. doi:10.1053/j.gastro.2016.08.029
   PubMed Web of Science ®Google Scholar
• Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable hepatocellular carcinoma: the LEGACY study. Hepatology. 2021;74(5):2342–2352. doi:10.1002/hep.31819
   PubMed Web of Science ®Google Scholar
• Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomized, muticentre, open-label Phase 2 trial. Lancet Gastroenerol Hepatol. 2021;6(1):17–29. doi:10.1016/S2468-1253(20)30290-9
   PubMed Web of Science ®Google Scholar
• Salem R, Padia SA, Lam M, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019;46(8):1695–1704. doi:10.1007/s00259-019-04340-5
   PubMed Web of Science ®Google Scholar
• Lam M, Salem S, Garin E A global study of advanced dosimetry in the treatment of hepatocellular carcinoma with Yttrium-90 glass microspheres: analyses from the TARGET study. Late-Breaking Oral Presentation at the Society of Interventional Radiology Annual Scientific Meeting. Virtual Congress; March 20–26, 2021.
   Google Scholar
• Chan KT, Alessio AM, Johnson GE, et al. Prospective trial using internal pair-production positron emission tomography to establish the Yttrium-90 radioembolization dose required for response of hepatocellular carcinoma. Int J Radiat Oncol Bio Phys. 2018;101(2):358–365. doi:10.1016/j.ijrobp.2018.01.116
   PubMed Web of Science ®Google Scholar
• Garin E, Rolland Y, Pracht M, et al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microsphere radioembolization. Liver Int. 2017;37(1):101–110. doi:10.1111/liv.13220
   PubMed Web of Science ®Google Scholar
• Estrade F, Lescure C, Muzellec L, et al. Lymphocytes and neutrophil-to-lymphocyte ratio variations after selective internal radiation treatment of HCC: a retrospective cohort study. Cardiovasc Intervent Radiol. 2020;43(8):1175–1181. doi:10.1007/s00270-020-02467-9
   PubMed Web of Science ®Google Scholar
• Venkatesulu BP, Mallick S, Lin SH, Krishnan S. A systemic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol. 2018;123:42–51. doi:10.1016/j.critrevonc.2018.01.003
   PubMed Web of Science ®Google Scholar
• Domouchtsidou A, Barsegian V, Mueller SP, et al. Impaired lymphocyte function in patients with hepatic malignancies after selective internal radiotherapy. Cancer Immunol Immunother. 2018;67(5):843–853. doi:10.1007/s00262-018-2141-0
   PubMed Web of Science ®Google Scholar
• Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl. 2004;10:S107–110. doi:10.1002/lt.20036
   PubMedGoogle Scholar
• Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16(12):1627–1639. doi:10.1097/01.RVI.0000184594.01661.81
   PubMed Web of Science ®Google Scholar
• Dunfee BL, Riaz A, Lewandowski RJ, et al. Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival. J Vasc Interv Radiol. 2010;21(1):90–95. doi:10.1016/j.jvir.2009.09.011
   PubMed Web of Science ®Google Scholar
• Li X, Montazeri SA, Paz-Fumagalli R, et al. Prognostic significance of neutrophil to lymphocyte ratio dynamics in patients with hepatocellular carcinoma treated with radioembolization using glass microspheres. Eur J Nucl Med Mol Imaging. 2021;48(8):2624–2634. doi:10.1007/s00259-020-05186-y
   PubMed Web of Science ®Google Scholar
• Gok Yavuz B, Hasanov E, Lee SS, et al. Current landscape and future directions of biomarkers for immunotherapy in hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1195–1207. doi:10.2147/JHC.S322289
   PubMed Web of Science ®Google Scholar
• Greten TF, Mauda-Havakuk M, Heinrich B, Korangy F, Wood BJ. Combined locoregional-immunotherapy for liver cancer. J Hepatol. 2019;70(5):999–1007. doi:10.1016/j.jhep.2019.01.027
   PubMed Web of Science ®Google Scholar
• Chew V, Lee YH, Pan L, et al. Immune activation underlies a sustained clinical response to yttrium-90 radioembolisation in hepatocellular carcinoma. Gut. 2019;68(2):335–346. doi:10.1136/gutjnl-2017-315485
   PubMed Web of Science ®Google Scholar
• Camphausen K, Moses MA, Menard C, et al. Radiation abscopal antitumor effect is mediated through p53. Cancer Res. 2003;63(8):1990–1993.
   PubMed Web of Science ®Google Scholar
• Filatenkov A, Baker J, Mueller AM, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res. 2015;21(16):3727–3739. doi:10.1158/1078-0432.CCR-14-2824
   PubMed Web of Science ®Google Scholar
• Nagai S, Abouljoud MS, Kazimi M, Brown KA, Moonka D, Yoshida A. Peritransplant lymphopenia is a novel prognostic factor in recurrence of hepatocellular carcinoma after liver transplantation. Transplantation. 2014;97(6):694–701. doi:10.1097/01.TP.0000437426.15890.1d
   PubMed Web of Science ®Google Scholar
• Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med. 1999;5(1):83–89. doi:10.1038/4772
   PubMed Web of Science ®Google Scholar
• Garin E, Lenoir L, Edeline J, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40(7):1057–1068. doi:10.1007/s00259-013-2395-x
   PubMed Web of Science ®Google Scholar
• Chiesa C, Mira M, Bhoori S, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: treatment optimization using the dose-toxicity relationship. Eur J Nucl Med Mol Imaging. 2020;47(13):3018–3032. doi:10.1007/s00259-020-04845-4
   PubMed Web of Science ®Google Scholar